FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2315662264> ?p ?o ?g. }

• W2315662264 endingPage "v1" @default.
• W2315662264 startingPage "v1" @default.
• W2315662264 abstract "ABSTRACT Aim: Background: The highly selective, anti-PD-1 humanized monoclonal antibody pembro has shown antitumor activity in several solid tumors, including HNC. We present updated safety, tolerability, and antitumor activity of pembro for recurrent/metastatic HNC (Clinicaltrials.gov: NCT01848834). Methods: During screening, PD-L1 expression in archival or newly obtained tumor samples was assessed using a prototype immunohistochemistry assay; PD-L1 expression in stroma or ≥1% of tumor cells was required for study entry. Pembro 10 mg/kg was given every 2 wk until complete response, progression, unacceptable toxicity, physician decision, or consent withdrawal. Adverse events (AEs) were recorded throughout the study. Response was assessed every 8 wk. Primary end point was overall response rate (ORR) per RECIST v1.1. Results: Out of 104 HNC pts screened, 81 (78%) were PD-L1-positive, 61 enrolled, and 60 received ≥1 pembro dose: 23 HPV+, 37 HPV-. After a median follow-up of 10.2 mo, 15 pts (25%) remain on pembro. ORR (confirmed + unconfirmed) per RECIST v1.1 by investigator review was 20%, and response duration ranged from 8+ to 41+ weeks (median not reached). 9 of 11 responders had a smaller target lesion burden (ie, sum below the median) at baseline. ORR was similar in HPV+ and HPV- pts, whereas PFS and OS were longer in HPV+ pts (Table). PD-L1 expression was positively correlated with ORR (P = 0.018) and PFS (P = 0.024). ORR was 50% in the 12 pts with high PD-L1 expression. Drug-related AEs of any grade occurred in 58% of pts (grade ≥3 in 17%). The most common drug-related AEs were fatigue (18%), pruritus (10%), and nausea (8%). There were no drug-related deaths. Conclusions: Pembro is safe and tolerable and shows antitumor activity in both HPV+ and HPV- advanced HNC. These findings support further development of pembro in advanced HNC. Overall N = 61* HPV+ n = 23* HPV– n = 38* ORR, n (%) 11 (20) 4 (20) 7 (19) Median PFS (95% CI), wk 9.3 (8.0-20.1) 17.2 (8.0-41.7) 8.1 (7.9-15.6) Median OS (95% CI), mo 12.6 (8.2-12.6) NR (9.6-NR) 9.5 (3.9-12.6) *ORR and PFS were evaluated in the 56 pts (20 HPV+, 36 HPV-) who received ≥1 pembro dose and had measurable disease per RECIST v1.1 by investigator review. Disclosure: L.Q. Chow: Advisory Board Member for Bristol Myers Squibb, Novartis, Celgene; Research funding from Bristol Myers Squibb, Novartis, AstraZeneca/Medimmune, Genentech/Roche, VentiRx, Pfizer, Lily/Imclone; B. Burtness: Advisory board membership for VentiRx and Novartis; Research funding from Merck, Genentech, Boehringer Ingelheim, and Pfizer; E.J. Gonzalez, J.K. Lunceford, C. Gause and J.D. Cheng: Employee of and stock ownership in Merck Sharp & Dohme, a subsidiary of Merck & Co, Inc.; J. Pulini, J. Johnson, M. Dolled-Filhart, K. Emancipator and K. Pathiraja: Employee of Merck Sharp & Dohme, a subsidiary of Merck & Co, Inc.; T. Seiwert: Advisory board membership for Novartis and Onyx/Bayer; Research funding from Boehringer Ingelheim and Genentech; Honoraria from Merck. All other authors have declared no conflicts of interest." @default.
• W2315662264 created "2016-06-24" @default.
• W2315662264 creator A5001287707 @default.
• W2315662264 creator A5008467612 @default.
• W2315662264 creator A5022384270 @default.
• W2315662264 creator A5023000705 @default.
• W2315662264 creator A5045982804 @default.
• W2315662264 creator A5048506927 @default.
• W2315662264 creator A5048903763 @default.
• W2315662264 creator A5058894394 @default.
• W2315662264 creator A5061867713 @default.
• W2315662264 creator A5062199973 @default.
• W2315662264 creator A5062557677 @default.
• W2315662264 creator A5070256948 @default.
• W2315662264 creator A5084659842 @default.
• W2315662264 creator A5088734038 @default.
• W2315662264 creator A5089998052 @default.
• W2315662264 date "2014-09-01" @default.
• W2315662264 modified "2023-09-30" @default.
• W2315662264 title "A Phase Ib Study of Pembrolizumab (Pembro; Mk-3475) in Patients (Pts) with Human Papiilloma Virus (Hpv)-Positive and Negative Head and Neck Cancer (Hnc)" @default.
• W2315662264 doi "https://doi.org/10.1093/annonc/mdu438.32" @default.
• W2315662264 hasPublicationYear "2014" @default.
• W2315662264 type Work @default.
• W2315662264 sameAs 2315662264 @default.
• W2315662264 citedByCount "25" @default.
• W2315662264 countsByYear W23156622642015 @default.
• W2315662264 countsByYear W23156622642016 @default.
• W2315662264 countsByYear W23156622642017 @default.
• W2315662264 countsByYear W23156622642018 @default.
• W2315662264 countsByYear W23156622642019 @default.
• W2315662264 countsByYear W23156622642020 @default.
• W2315662264 countsByYear W23156622642021 @default.
• W2315662264 countsByYear W23156622642022 @default.
• W2315662264 countsByYear W23156622642023 @default.
• W2315662264 crossrefType "journal-article" @default.
• W2315662264 hasAuthorship W2315662264A5001287707 @default.
• W2315662264 hasAuthorship W2315662264A5008467612 @default.
• W2315662264 hasAuthorship W2315662264A5022384270 @default.
• W2315662264 hasAuthorship W2315662264A5023000705 @default.
• W2315662264 hasAuthorship W2315662264A5045982804 @default.
• W2315662264 hasAuthorship W2315662264A5048506927 @default.
• W2315662264 hasAuthorship W2315662264A5048903763 @default.
• W2315662264 hasAuthorship W2315662264A5058894394 @default.
• W2315662264 hasAuthorship W2315662264A5061867713 @default.
• W2315662264 hasAuthorship W2315662264A5062199973 @default.
• W2315662264 hasAuthorship W2315662264A5062557677 @default.
• W2315662264 hasAuthorship W2315662264A5070256948 @default.
• W2315662264 hasAuthorship W2315662264A5084659842 @default.
• W2315662264 hasAuthorship W2315662264A5088734038 @default.
• W2315662264 hasAuthorship W2315662264A5089998052 @default.
• W2315662264 hasBestOaLocation W23156622641 @default.
• W2315662264 hasConcept C121608353 @default.
• W2315662264 hasConcept C126322002 @default.
• W2315662264 hasConcept C141071460 @default.
• W2315662264 hasConcept C143998085 @default.
• W2315662264 hasConcept C159047783 @default.
• W2315662264 hasConcept C2776530083 @default.
• W2315662264 hasConcept C2777701055 @default.
• W2315662264 hasConcept C2780057760 @default.
• W2315662264 hasConcept C3018411727 @default.
• W2315662264 hasConcept C71924100 @default.
• W2315662264 hasConceptScore W2315662264C121608353 @default.
• W2315662264 hasConceptScore W2315662264C126322002 @default.
• W2315662264 hasConceptScore W2315662264C141071460 @default.
• W2315662264 hasConceptScore W2315662264C143998085 @default.
• W2315662264 hasConceptScore W2315662264C159047783 @default.
• W2315662264 hasConceptScore W2315662264C2776530083 @default.
• W2315662264 hasConceptScore W2315662264C2777701055 @default.
• W2315662264 hasConceptScore W2315662264C2780057760 @default.
• W2315662264 hasConceptScore W2315662264C3018411727 @default.
• W2315662264 hasConceptScore W2315662264C71924100 @default.
• W2315662264 hasLocation W23156622641 @default.
• W2315662264 hasOpenAccess W2315662264 @default.
• W2315662264 hasPrimaryLocation W23156622641 @default.
• W2315662264 hasRelatedWork W1993267564 @default.
• W2315662264 hasRelatedWork W2007176132 @default.
• W2315662264 hasRelatedWork W2062927577 @default.
• W2315662264 hasRelatedWork W2318228201 @default.
• W2315662264 hasRelatedWork W2529376761 @default.
• W2315662264 hasRelatedWork W2906023247 @default.
• W2315662264 hasRelatedWork W4255986856 @default.
• W2315662264 hasRelatedWork W4324130824 @default.
• W2315662264 hasRelatedWork W4361014962 @default.
• W2315662264 hasRelatedWork W2524104600 @default.
• W2315662264 hasVolume "25" @default.
• W2315662264 isParatext "false" @default.
• W2315662264 isRetracted "false" @default.
• W2315662264 magId "2315662264" @default.
• W2315662264 workType "article" @default.